News

Filter

Current filters:

Forest Laboratories

1 to 9 of 405 results

FDA accepts Actavis NDA for eluxadoline

FDA accepts Actavis NDA for eluxadoline

03-09-2014

Ireland-headquartered generic drug major Actavis says that the US Food and Drug Administration has accepted…

ActaviseluxadolineForest LaboratoriesFuriex PharmaceuticalsGastro-intestinalsPharmaceuticalRegulationUSA

Actavis and Forest to divest four generics to gain FTC OK for merger

01-07-2014

In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Positive Ph III results with Forest Labs’ vilazodone in GAD

24-06-2014

US drugmaker Forest Laboratories has released positive top-line results from three Phase III trials evaluating…

Forest LaboratoriesNeurologicalPharmaceuticalResearchvilazodone

Forest appeases shareholders over Actavis deal

30-05-2014

US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

Adamas Pharma gets $25 million milestone from Forest Labs

21-05-2014

Adamas Pharmaceuticals says it has received a $25 million milestone payment from Forest Laboratories…

Adamas PharmaceuticalsFinancialForest LaboratoriesMDX-8704NeurologicalPharmaceuticalRegulationUSA

Actavis announces proposed Senior Leadership Team

Actavis announces proposed Senior Leadership Team

14-05-2014

US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead…

ActavisBiosimilarsBoardroomForest LaboratoriesPharmaceuticalUSA

Forest Labs sales top analysts’ forecasts

29-04-2014

US drugmaker Forest Laboratories, currently the subject of a takeover by Actavis, has reported diluted…

FinancialForest LaboratoriesPharmaceutical

1 to 9 of 405 results

Back to top